ProShare Advisors
CGEM icon

ProShare Advisors’s Cullinan Oncology CGEM Stock Holding History

ProShare Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,465
Closed -$149K – 1935
2026
Q1 		$149K Sell
10,465
-2,024
-16% -$26K ﹤0.01% 1651
2025
Q4 		$129K Buy
12,489
+1,661
+15% +$15K ﹤0.01% 1822
2025
Q3 		$64.2K Sell
10,828
-1,837
-15% -$13.5K ﹤0.01% 1904
2025
Q2 		$95.4K Sell
12,665
-1,288
-9% -$10.3K ﹤0.01% 1888
2025
Q1 		$106K Sell
13,953
-3,373
-19% -$32.4K ﹤0.01% 1822
2024
Q4 		$211K Buy
17,326
+4,124
+31% +$59.3K ﹤0.01% 1858
2024
Q3 		$221K Buy
+13,202
New +$234K ﹤0.01% 1669
2022
Q1 		– Sell
-11,810
Closed -$183K – 2223
2021
Q4 		$183K Buy
+11,810
New +$236K ﹤0.01% 2067

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ProShare Advisors's CGEM Position: Q2 2026 in Review

ProShare Advisors sold out of Cullinan Oncology (CGEM) in Q2 2026, closing a stake of 10,465 shares — an estimated $149K sold.

ProShare Advisors first reported a position in CGEM in Q4 2021 and held it in 8 quarters. The position peaked at $221K in Q3 2024. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • ProShare Advisors reported no remaining Cullinan Oncology position as of Q2 2026 after selling out during the quarter.
  • ProShare Advisors sold 10,465 Cullinan Oncology shares in Q2 2026, an estimated $149K.
  • ProShare Advisors first reported a position in Cullinan Oncology in Q4 2021 and held it in 8 quarters.
  • ProShare Advisors's Cullinan Oncology position peaked at $221K in Q3 2024.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.